a year ago
IMVT
AnalystsMatthew BarcusMatthew Barcus's Stock Forecasts
AnalystsMatthew Barcus
Sectors:
Industries:
Analyst Ranking
Top 25%
#1147 out of 4554 analysts
Average Return
+2.99%
Win Rate
21%6 out of 29
Risk vs Reward
Poor
Good
Matthew Barcus's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunovant IncIMVT | +639.59% | $5.38 | $39.79 | 2022-09-28 - 2023-09-28 | Strong Buy |
Immunome IncIMNM | +295.08% | $5.69 | $22.48 | 2023-03-16 - 2024-03-15 | Strong Buy |
Immunovant IncIMVT | +166.30% | $12.67 | $33.74 | 2022-11-06 - 2023-11-06 | Strong Buy |
Immunovant IncIMVT | +98.86% | $18.41 | $36.61 | 2023-02-05 - 2024-02-05 | Strong Buy |
Q32 Bio IncQTTB | +37.93% | $17.68 | $24.38 | 2023-05-11 - 2024-04-18 | Strong Buy |
Matthew Barcus Analyst Color
Get additional color on Matthew Barcus's coverage of popular stocks
a year ago
IMVT
Matthew Barcus's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Uniqure NvQURE | 4 | Strong Buy | $27.00 | +473.25% | Maintains | 10 months ago |
Zura Bio LtdZURA | 1 | Strong Buy | $14.00 | +279.40% | Initiates Coverage On | 10 months ago |
Xilio Therapeutics IncXLO | 3 | Strong Buy | $7.00 | +446.88% | Reiterates | a year ago |
Immunovant IncIMVT | 4 | Strong Buy | $32.00 | +12.99% | Maintains | a year ago |
Purple Biotech LtdPPBT | 3 | Strong Buy | $11.00 | +2,286.12% | Reiterates | a year ago |
Q32 Bio IncQTTB | 3 | Strong Buy | $126.00 | +416.82% | Maintains | a year ago |
Anixa Biosciences IncANIX | 3 | Strong Buy | $9.00 | N/A | Reiterates | a year ago |
Immunome IncIMNM | 1 | Strong Buy | $8.00 | N/A | Maintains | a year ago |
Applied Molecular Transport IncAMTI | 2 | Strong Buy | $3.00 | N/A | Reiterates | a year ago |
Oncorus IncONCR | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Vincerx Pharma IncVINC | 3 | Strong Buy | $3.00 | N/A | Maintains | a year ago |
Notable Labs LtdNTBL | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.